D-Lactic Acid

Summary

D-Lactic Acid (CHEMBL358850) is a phase-3 clinical-stage small molecule targeting HCAR1.

At a glance

• Status: Max clinical phase 3 (not approved)
• Modality: Small molecule
• Targets: 1 (HCAR1)
• Clinical trials: 88
• Chemistry: 90.08 Da · C3H6O3

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL358850
Name	D-Lactic Acid
Type	Small molecule
Max phase	3
FDA approved	no
PubChem CID	61503
ChEBI	CHEBI:42111
Molecular formula	C3H6O3
Molecular weight	90.08
InChIKey	JVTAAEKCZFNVCJ-UWTATZPHSA-N

SMILES: C[C@H](C(=O)O)O

IUPAC name: (2R)-2-hydroxypropanoic acid

ChEBI definition: An optically active form of lactic acid having (R)-configuration.

Other ChEBI roles (chemical / environmental): Escherichia coli metabolite, human metabolite.

Also known as: D-(-)-lactic acid, D-lactic acid, Lactic acid, d-, lactate, D-Lactate, Lactate, D-Lactic Acid, SID144211160, D-LACTIC ACID

Patent coverage: 9,096 distinct patent families (25,634 SureChEMBL compound mentions), from 1 matched compound structure(s). Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

Primary targets (GtoPdb curated mechanism): the Cancer dependency column is the DepMap CRISPR fitness signal (% of screened cell lines dependent on the target).

Gene	Target	Action	pAffinity	Cancer dependency	UniProt
HCAR1	HCA1 receptor	Partial agonist	2.52	0.6%	Q9BXC0

Bioactivity

No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).

Target pathways

Aggregated over 1 target gene(s): HCAR1.

Top Reactome pathways

2 total, by targets touching each:

Pathway	Targets	Genes
Hydroxycarboxylic acid-binding receptors	1	HCAR1
G alpha (i) signalling events	1	HCAR1

Dominant GO biological processes

GO term	Targets
G protein-coupled receptor signaling pathway	1
adenylate cyclase-inhibiting G protein-coupled receptor signaling pathway	1
negative regulation of lipid catabolic process	1
signal transduction	1

Indications & clinical

Indications

0 indications (0 at ChEMBL trial phase 4).

Clinical trials

Total trials: 88.

Phase distribution

Phase	Trials
Not specified	52
PHASE4	15
PHASE3	9
PHASE2	6
PHASE2/PHASE3	3
PHASE1/PHASE2	1
PHASE1	1
EARLY_PHASE1	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT06260878	PHASE4	RECRUITING	Short-term Intravenous Fluids for Prevention of Post-ERCP Pancreatitis
NCT07124130	PHASE4	RECRUITING	Lactated Ringer’s and Dextrose 5% vs Only Lactated Ringer’s in Labor
NCT07240701	PHASE4	NOT_YET_RECRUITING	Normal Saline Versus Ringer’s Lactate for Initial Fluid Resuscitation in Sepsis
NCT00542516	PHASE4	COMPLETED	Comparison Between Two Techniques of Volemic Expansion in Hip Replacement Arthroplasty
NCT00797589	PHASE4	COMPLETED	Effect of Prime Solution on Fluid Balance After Open Heart Surgery
NCT01387477	PHASE4	WITHDRAWN	Lactate to Treat Hypoglycemia
NCT01632046	PHASE4	COMPLETED	Administration of pH-Neutral Peritoneal Dialysis Solutions Containing Lactate or Bicarbonate in Children
NCT01692769	PHASE4	COMPLETED	Trial Of Normal Saline Versus Ringer’s Lactate In Paediatric Trauma Patients
NCT03764085	PHASE4	COMPLETED	Efficacy and Safety of Rheosorbilact® Solution for Infusion, in a Complex Therapy of Sepsis.
NCT03771170	PHASE4	COMPLETED	Efficacy and Safety of Rheosorbilact® Solution for Infusion, in a Complex Therapy of Peritonitis
NCT03799250	PHASE4	UNKNOWN	Fluid Management in the Post Anesthesia Care Unit
NCT03824457	PHASE4	COMPLETED	Efficacy and Safety of Rheosorbilact® Solution for Infusion, in a Complex Therapy of Pneumonia
NCT04152096	PHASE4	COMPLETED	Efficacy and Safety of Rheosorbilact® Solution for Infusion, in a Complex Therapy of Burns
NCT04512950	PHASE4	COMPLETED	Crystalloid FLUID Choices for Resuscitation of Hospitalized Patients
NCT05610254	PHASE4	COMPLETED	The Cold Fluids Study
NCT00529490	PHASE3	COMPLETED	Efficacy, Safety of Hypertonic Lactate Soln. as Fluid Resuscitation Compared With Ringer’s Lactate in Post-CABG Pats
NCT00529711	PHASE3	COMPLETED	The Efficacy of Hypertonic Lactate Solution in CABG(Coronary Artery Bypass Grafting) Patients
NCT00966628	PHASE3	UNKNOWN	Effect of Hypertonic Sodium Lactate on sVCAM-1 Level as Surrogate Marker of Endothelial Capillary Leakage in Pediatric Dengue Shock Syndrome Patients (DSS)
NCT01433276	PHASE3	COMPLETED	Efficacy, Safety of Solution Containing Hyperosmolar Sodium Lactate Infusion for Resuscitation of Patients With Hemorrhagic Shock
NCT02634255	PHASE3	UNKNOWN	The Onset Time of Rocuronium in Emergency and Elective Surgery
NCT02709044	PHASE2/PHASE3	UNKNOWN	Fluid Resuscitation in Acute Pancreatitis
NCT03043131	PHASE3	UNKNOWN	Comparative Analysis Between Ringer’s Lactate vs Plasma Lyte-A as Cardiopulmonary Bypass Prime
NCT03118362	PHASE3	COMPLETED	Fluid Resuscitation in Burn Patients
NCT05223361	PHASE3	COMPLETED	Cardiopulmonary Bypass Prime Solution in Patients Undergoing Heart Valve Surgery
NCT05658406	PHASE2/PHASE3	COMPLETED	Supplemental Perioperative Intravenous Crystalloids for Postoperative Nausea and Vomiting in Children Undergoing Oncological Surgery
NCT06110429	PHASE3	UNKNOWN	Sodium Lactate Versus Hypertonic Saline Solution in the Treatment of Intracranial Hypertensive Episodes in Severe Brain Injured Patients
NCT06461390	PHASE2/PHASE3	COMPLETED	The Effect of Early Norepinephrine on Stroke Volume Index, Cardiac Index, Lactate, and Arterial Elastance in Pediatric Septic Shock
NCT06487299	PHASE2	NOT_YET_RECRUITING	Iron Administration Via Colonic TET Combined With WMT for ID
NCT00425334	PHASE2	COMPLETED	Safety Study of Hemospan® in Prostatectomy Patients
NCT00494949	PHASE1/PHASE2	COMPLETED	Increasing Dose Safety Study of Hemospan in Orthopedic Surgery Patients
NCT02558543	PHASE2	TERMINATED	Subcutaneous Injection of Autologous Adipose Tissue-derived Stromal Vascular Fraction Into the Fingers of Patients With Systemic Sclerosis
NCT02866552	PHASE2	UNKNOWN	SCLERoderma et Adipose-DErived Stroma Cells
NCT03697330	PHASE2	COMPLETED	Liberal Versus Restrictive Fluid Protocols in Adults
NCT04858139	PHASE2	TERMINATED	Exploring the Effect of Lactate Administration After Ischemic Stroke on Brain Metabolism
NCT06622499	PHASE1	COMPLETED	The Colder Fluids - Intravenous Infusion of 10 Degrees Celsius Fluids and Its Effects on Circulation and Hemostasis
NCT06825143	EARLY_PHASE1	NOT_YET_RECRUITING	Therapeutic Strategies to Reduce Endothelial Ischemia-reperfusion Injury
NCT04043598	Not specified	RECRUITING	Crystalloid Fluid Choice and Neurological Outcome in Patients After Subarachnoid Haemorrhage
NCT06400355	Not specified	ACTIVE_NOT_RECRUITING	Effect of Mannitol on Recovery Pattern After Orthognathic Surgery
NCT06499701	Not specified	RECRUITING	Volume Kinetics of Fluid Resuscitation in Early Sepsis
NCT06597253	Not specified	ACTIVE_NOT_RECRUITING	A Single-centre Study Comparing a Non-invasive Lactate Sensor to Standard Invasive Measurements in Patients Undergoing Coronary Artery Bypass Surgery.

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

Molecules sharing ≥1 of this drug’s curated primary targets, merged from two biobtree sources and ranked by shared-target count, then clinical phase: ChEMBL clinical-stage candidates (development phase ≥2) and PubChem drug-class bioactivity (approved / known drugs acting on the target). Deduplicated by drug name; the drug’s own salt forms are excluded. Note: for a drug with few primary targets a shared-target match can reflect off-target / promiscuous binding rather than the same therapeutic mechanism — the phase ordering surfaces bona-fide therapeutics first.

3 molecules share ≥1 primary target. Top 3 by shared-target count:

Molecule	Source	Status	Shared targets
lactic acid, l-	PubChem	Approved	HCAR1
niacin	PubChem	Approved	HCAR1
oxybate	PubChem	Approved	HCAR1